PRLD - Wall Street Estimates - Prelude Therapeutics Incorporated

Healthcare - Biotechnology - NASDAQ - US

$ 0.7352

-3.14 %

$ 40.5 M

Market Cap

-0.42

P/E

Price Target Average

580.09%

Revenue Forecast Estimate

-0.00%

EBIT Estimate

25.99%

Net Income Estimate

14.54%

WALL STREET ESTIMATES

Wall Street Analysts Price Targets Prelude Therapeutics Incorporated

Wall Street analysts predict an average 1-year price target for PRLD of $5 , with forecasts ranging from a low of $3 to a high of $7 .

PRLD Lowest Price Target Wall Street Target

3 USD 308.05%

PRLD Average Price Target Wall Street Target

5 USD 580.09%

PRLD Highest Price Target Wall Street Target

7 USD 852.12%

REVENUE FORECAST

EBIT FORECAST

NET INCOME FORECAST

Free